A transformative chapter in India’s healthcare journey has begun with the launch of EarlySure Diagnostics Limited, a pioneering venture committed to revolutionizing advanced cancer diagnostics across the country. As the exclusive partner of global liquid biopsy leader IMBDx Inc., EarlySure aims to reshape cancer detection and management through minimally invasive, highly precise, and accessible diagnostic solutions.
At the helm of this movement are two dynamic leaders — Simrithi Bathija, Miss India International titleholder turned Co-Founder & Chief Marketing Officer, and Pritam Lodh, Co-Founder & Chief Technical Officer — combining vision, compassion, and scientific innovation to create lasting health impact.
For Simrithi Bathija, her pageant win was the beginning of a purpose-driven mission that bridges wellness, awareness, and advocacy. She believes that “a fit mind and a fit body can change the way we live,” urging individuals to take charge of their health. As CMO, she aligns her mission with the Prime Minister’s Swasth Bharat (Healthy India) initiative, emphasizing that “preventive healthcare and awareness are not optional anymore — they are the strongest shield we can give ourselves and our families.” With India’s cancer burden projected to rise by 12.8% by 2025, her advocacy is critical in making preventive screening and early diagnosis mainstream.
On the scientific front, Pritam Lodh leads EarlySure’s precision oncology initiatives. With strong academic credentials — including an MSc in Biotechnology and an MBA in International Business — he is driving the company’s collaboration with IMBDx, whose liquid biopsy and Comprehensive Genomic Profiling (CGP) technologies eliminate the need for invasive tissue sampling.
Leveraging Next-Generation Sequencing (NGS) and AI-driven bioinformatics, these tests analyze cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) to enable early cancer detection, tumor monitoring, personalized treatment planning, and reduced patient discomfort.
As Lodh explains, “The future of oncology is non-invasive and predictive. We are not just bringing a test to India; we are delivering hope, accuracy, and a faster pathway to personalized treatment that bypasses the limitations and pain points of conventional methods.” He adds, “By adopting IMBDx’s CancerDetect™ and CancerFind™ solutions, we are providing clinicians with actionable insights earlier, moving cancer care from late-stage reaction to true prevention and optimal therapeutic strategy.”
Through IMBDx’s AlphaLiquid® and CancerDetect™ platforms — offering comprehensive genomic profiling, multi-cancer early detection, and personalized MRD assays — EarlySure brings global innovation to Indian clinicians with rapid turnaround times and high analytical sensitivity.
Together, Simrithi Bathija and Pritam Lodh are shaping a new paradigm where science, purpose, and accessibility intersect — proving that true leadership in healthcare is not just about innovation, but about empowering lives and inspiring change.
Also Read